ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.625,55
-0,33%
S&P 500
5.267,84
0,00%
Dow Jones
39.065,26
0,00%
Euro vs US Dollar
1,08434
0,29%
Bitcoin
67.412,44
-0,75%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Kinnate Biopharma Inc (KNTE)

  7. Kinnate Biopharma Inc (KNTE) News

KNTE

Kinnate Biopharma (KNTE)

Kinnate Biopharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:KNTE
DatumZeitQuelleÜberschriftSymbolFirma
03/04/202415h00GlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:KNTEKinnate Biopharma Inc
19/03/202421h05GlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:KNTEKinnate Biopharma Inc
05/03/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
05/03/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
04/03/202423h27Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:KNTEKinnate Biopharma Inc
01/03/202414h53Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:KNTEKinnate Biopharma Inc
01/03/202414h50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
01/03/202414h35PR Newswire (US)Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
01/03/202414h35PR Newswire (US)Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
01/03/202414h35PR Newswire (Canada)Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
01/03/202414h30GlobeNewswire Inc.Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre LaboratoriesNASDAQ:KNTEKinnate Biopharma Inc
21/02/202412h01Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:KNTEKinnate Biopharma Inc
16/02/202423h57PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.NASDAQ:KNTEKinnate Biopharma Inc
16/02/202416h46PR Newswire (US)Kuehn Law Encourages KNTE, FANG, HAYN, and VINE Investors to Contact Law FirmNASDAQ:KNTEKinnate Biopharma Inc
16/02/202415h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
16/02/202414h00GlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:KNTEKinnate Biopharma Inc
16/02/202414h00GlobeNewswire Inc.Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per ShareNASDAQ:KNTEKinnate Biopharma Inc
14/02/202415h21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KNTEKinnate Biopharma Inc
16/01/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
05/12/202323h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
05/12/202323h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
15/11/202315h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
09/11/202322h21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KNTEKinnate Biopharma Inc
09/11/202322h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
09/11/202322h05GlobeNewswire Inc.Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:KNTEKinnate Biopharma Inc
18/09/202322h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNTEKinnate Biopharma Inc
18/09/202322h10GlobeNewswire Inc.Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce RestructuringNASDAQ:KNTEKinnate Biopharma Inc
06/09/202323h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
06/09/202323h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNTEKinnate Biopharma Inc
08/08/202322h48Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KNTEKinnate Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:KNTE

Kürzlich von Ihnen besucht

AMEX
XLF
Financial Select Sector
NYSE
KO
Coca Cola
USOTC
DTEGY
Deutsche Telekom (QX)
TG
ALV
Allianz
CCOM
US100
US Tech 100
TG
BAYN
Bayer
DBI
MDAX
MDAX
FX
EURUSD
Euro vs US Dollar
NASDAQ
AAPL
Apple
CCOM
SILVER
SILVER
NASDAQ
GOOGL
Alphabet
USOTC
BASFY
BASF (QX)
TG
TUI1
Tui
FX
EURJPY
Euro vs Yen
TG
MBG
MercedesBenz
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten